PAVmed Inc. entered into subscription agreements for the private placement of 13,625 series A convertible preferred stock at an issue price of $1,000 per share for gross proceeds of $13,625,000 on March 7, 2023. The transaction included participation certain accredited investors. In connection with the offering the company filed a Certificate of Designation of Preferences, Rights and Limitations of the Series A Preferred Stock with the Secretary of State of the State of Delaware.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.71 USD | -0.58% | -9.04% | -58.50% |
Mar. 27 | Transcript : PAVmed Inc., Q4 2023 Earnings Call, Mar 27, 2024 | |
Mar. 25 | PAVmed Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-58.50% | 15.68M | |
+8.69% | 220B | |
+6.69% | 183B | |
+10.90% | 133B | |
+25.41% | 107B | |
-0.19% | 63.05B | |
+12.72% | 51.74B | |
+3.96% | 50.47B | |
+0.40% | 40.91B | |
+15.03% | 40.59B |
- Stock Market
- Equities
- PAVM Stock
- News PAVmed Inc.
- PAVmed Inc. announced that it has received $13.625 million in funding